home / stock / ogen / ogen short
Short Information | Oragenics Inc. (NYSE:OGEN)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 25,601 |
Total Actual Volume | 1,157,971 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,280 |
Average Short Percentage | 2.64% |
Is there a OGEN Short Squeeze or Breakout about to happen?
See the OGEN Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-24-2024 | $1.11 | $1.09 | $1.11 | $1.05 | 9,180 | 1,110 | 12.09% |
04-23-2024 | $1.07 | $1.09 | $1.09 | $1.03 | 18,832 | 1,105 | 5.87% |
04-22-2024 | $1.1 | $1.06 | $1.13 | $1.04 | 15,021 | 1,355 | 9.02% |
04-19-2024 | $1.16 | $1.13 | $1.22 | $1.13 | 15,554 | 27 | 0.17% |
04-18-2024 | $1.1328 | $1.13 | $1.16 | $1.11 | 23,459 | 157 | 0.67% |
04-17-2024 | $1.02 | $1.08 | $1.135 | $1.015 | 71,803 | 9 | 0.01% |
04-16-2024 | $1.2 | $1.08 | $1.24 | $1.05 | 124,079 | 1,631 | 1.31% |
04-15-2024 | $1.19 | $1.22 | $1.3 | $1.15 | 41,814 | 484 | 1.16% |
04-12-2024 | $1.27 | $1.23 | $1.27 | $1.17 | 19,913 | 213 | 1.07% |
04-11-2024 | $1.24 | $1.23 | $1.29 | $1.1761 | 47,863 | 1,259 | 2.63% |
04-10-2024 | $1.34 | $1.2 | $1.42 | $1.17 | 168,695 | 1,316 | 0.78% |
04-09-2024 | $1.33 | $1.27 | $1.33 | $1.27 | 46,442 | 40 | 0.09% |
04-08-2024 | $1.18 | $1.33 | $1.33 | $1.17 | 81,096 | 1,914 | 2.36% |
04-05-2024 | $1.2 | $1.16 | $1.27 | $1.16 | 101,461 | 1,136 | 1.12% |
04-04-2024 | $1.31 | $1.18 | $1.375 | $1.16 | 107,130 | 2,267 | 2.12% |
04-03-2024 | $1.49 | $1.32 | $1.49 | $1.3 | 119,849 | 10,275 | 8.57% |
04-02-2024 | $1.41 | $1.47 | $1.48 | $1.4 | 52,537 | 357 | 0.68% |
04-01-2024 | $1.43 | $1.43 | $1.49 | $1.4 | 31,219 | 397 | 1.27% |
03-28-2024 | $1.41 | $1.44 | $1.47 | $1.4 | 25,707 | 320 | 1.24% |
03-27-2024 | $1.45 | $1.4 | $1.45 | $1.38 | 36,317 | 229 | 0.63% |
News, Short Squeeze, Breakout and More Instantly...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April ...
Oragenics, Inc. (the “Company”) (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has filed its annual report on March 29, 2024. The Company is pleased to report it has execu...
Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James “Jim” Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II ...